Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation
AA Quyyumi,
N Dakak,
JG Diodati,
DM Gilligan,
JA Panza,
and
RO Cannon 3rd
Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892-1650, USA. quyyumia@gwgate.nhlbi.nih.gov
OBJECTIVES: We hypothesized that L-arginine would improve abnormal coronary vasodilation in response to physiologic stress in patients with atherosclerosis and its risk factors by reversing coronary endothelial dysfunction. BACKGROUND: Studies have demonstrated that physiologic coronary vasodilation correlates with endothelial function and that L-arginine, the substrate for nitric oxide synthesis, improves the response to acetylcholine (Ach). METHODS: Changes in coronary blood flow and epicardial diameter response to Ach, adenosine and cardiac pacing were measured in 32 patients with coronary atherosclerosis or its risk factors and in 7 patients without risk factors and normal coronary angiograms. RESULTS: Intracoronary L-arginine did not alter baseline coronary vascular tone, but the epicardial and microvascular responses to Ach were enhanced (both p < 0.001). The improvement after L-arginine was greater in epicardial segments that initially constricted with Ach; similarly, L-arginine abolished microvascular constriction produced by higher doses of Ach. Thus, there was a negative correlation between the initial epicardial and vascular resistance responses to Ach and the magnitude of improvement with L-arginine (r = -0.55 and r = -0.50, respectively, p < 0.001). D-Arginine did not affect the responses to Ach, and adenosine responses were unchanged with L-arginine. Cardiac pacing-induced epicardial constriction was abolished by L-arginine, but microvascular dilation remained unaffected. CONCLUSIONS: Thus, L-arginine improved endothelium-dependent coronary epicardial and microvascular function in patients with endothelial dysfunction. Prevention of epicardial constriction during physiologic stress by L-arginine in patients with endothelial dysfunction may be of therapeutic value in the treatment of myocardial ischemia.
This article has been cited by other articles:

|
 |

|
 |
 
S. E. S. Miner, A. Al-Hesayen, L. E. Nield, T. Gori, and J. D. Parker
Acetylcholine acutely modifies nitric oxide synthase function in the human coronary circulation
Exp Physiol,
December 1, 2010;
95(12):
1167 - 1176.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. J. Suuronen, S. Hazra, P. Zhang, R. Vincent, P. Kumarathasan, Y. Zhang, J. Price, V. Chan, F. W. Sellke, T. G. Mesana, et al.
Impairment of human cell-based vasculogenesis in rats by hypercholesterolemia-induced endothelial dysfunction and rescue with L-arginine supplementation
J. Thorac. Cardiovasc. Surg.,
January 1, 2010;
139(1):
209 - 216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.H. W. Tang, Z. Wang, L. Cho, D. M. Brennan, and S. L. Hazen
Diminished Global Arginine Bioavailability and Increased Arginine Catabolism as Metabolic Profile of Increased Cardiovascular Risk
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2061 - 2067.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kakoki, H.-S. Kim, C.-J. S. Edgell, N. Maeda, O. Smithies, and D. L. Mattson
Amino acids as modulators of endothelium-derived nitric oxide
Am J Physiol Renal Physiol,
August 1, 2006;
291(2):
F297 - F304.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Voisine, J. Li, C. Bianchi, T. A. Khan, M. Ruel, S.-H. Xu, J. Feng, A. Rosinberg, T. Malik, Y. Nakai, et al.
Effects of L-Arginine on Fibroblast Growth Factor 2-Induced Angiogenesis in a Model of Endothelial Dysfunction
Circulation,
August 30, 2005;
112(9_suppl):
I-202 - I-207.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Voisine, C. Bianchi, T. A. Khan, M. Ruel, S.-H. Xu, J. Feng, J. Li, T. Malik, A. Rosinberg, and F. W. Sellke
Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of L-arginine in a porcine model of endothelial dysfunction
J. Thorac. Cardiovasc. Surg.,
June 1, 2005;
129(6):
1414 - 1420.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Zhang, T. W. Hein, W. Wang, M. W. Miller, T. W. Fossum, M. M. McDonald, J. D. Humphrey, and L. Kuo
Upregulation of Vascular Arginase in Hypertension Decreases Nitric Oxide-Mediated Dilation of Coronary Arterioles
Hypertension,
December 1, 2004;
44(6):
935 - 943.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.E.S. Miner, A. Al-Hesayen, S. Kelly, T. Benson, J.J. Thiessen, V.R. Young, and J.D. Parker
L-Arginine Transport in the Human Coronary and Peripheral Circulation
Circulation,
March 16, 2004;
109(10):
1278 - 1283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Pernow, F. Bohm, E. Beltran, and A. Gonon
L-Arginine protects from ischemia-reperfusion-induced endothelial dysfunction in humans in vivo
J Appl Physiol,
December 1, 2003;
95(6):
2218 - 2222.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
M. Ruel, G. F. Wu, T. A. Khan, P. Voisine, C. Bianchi, J. Li, J. Li, R. J. Laham, and F. W. Sellke
Inhibition of the Cardiac Angiogenic Response to Surgical FGF-2 Therapy in a Swine Endothelial Dysfunction Model
Circulation,
September 9, 2003;
108(2011):
II-335 - II-340.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M Bode-Boger, J. Muke, A. Surdacki, G. Brabant, R. H Boger, and J. C Frolich
Oral L-arginine improves endothelial function in healthy individuals older than 70 years
Vascular Medicine,
May 1, 2003;
8(2):
77 - 81.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Weis and J. P. Cooke
Cardiac Allograft Vasculopathy and Dysregulation of the NO Synthase Pathway
Arterioscler Thromb Vasc Biol,
April 1, 2003;
23(4):
567 - 575.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Nakamura, S. Al-Ruzzeh, A. H. Chester, A. Dewar, S. Rothery, N. J. Severs, M. H. Yacoub, and M. Amrani
Age-related changes in the protective effect of chronic administration of L-arginine on post-ischemic recovery of endothelial function
Eur J Cardiothorac Surg,
April 1, 2003;
23(4):
626 - 632.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. L. Houghton, E. F. Philbin, D. S. Strogatz, M. T. Torosoff, S. A. Fein, P. A. Kuhner, V. E. Smith, and A. A. Carr
The presence of African American race predicts improvement in coronary endothelial function after supplementary L-arginine
J. Am. Coll. Cardiol.,
April 17, 2002;
39(8):
1314 - 1322.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Nakamura, I. Schmidt, C. C. Gray, A. Dewar, S. Rothery, N. J. Severs, M. H. Yacoub, and M. Amrani
The effect of chronic L-arginine administration on vascular recovery following cold cardioplegic arrest in rats
Eur J Cardiothorac Surg,
April 1, 2002;
21(4):
753 - 759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. O. Cannon III
Oral L-arginine (and other active ingredients) for ischemic heart disease?
J. Am. Coll. Cardiol.,
January 2, 2002;
39(1):
46 - 48.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Imamura, S. Biro, T. Kihara, S. Yoshifuku, K. Takasaki, Y. Otsuji, S. Minagoe, Y. Toyama, and C. Tei
Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors
J. Am. Coll. Cardiol.,
October 1, 2001;
38(4):
1083 - 1088.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D Tousoulis, G J Davies, C Tentolouris, G Goumas, C Stefanadis, and P Toutouzas
Vasomotor effects of L- and D-arginine in stenotic atheromatous coronary plaque
Heart,
September 1, 2001;
86(3):
296 - 301.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Schwartz and M. G. Bourassa
Evaluation of Patients With Chest Pain and Normal Coronary Angiograms
Arch Intern Med,
August 13, 2001;
161(15):
1825 - 1833.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Behr-Roussel, A. Rupin, S. Simonet, E. Bonhomme, S. Coumailleau, A. Cordi, B. Serkiz, J.-N. Fabiani, and T. J. Verbeuren
Effect of Chronic Treatment With the Inducible Nitric Oxide Synthase Inhibitor N-Iminoethyl-L-Lysine or With L-Arginine on Progression of Coronary and Aortic Atherosclerosis in Hypercholesterolemic Rabbits
Circulation,
August 29, 2000;
102(9):
1033 - 1038.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Blum, L. Hathaway, R. Mincemoyer, W. H. Schenke, M. Kirby, G. Csako, M. A. Waclawiw, J. A. Panza, and R. O. Cannon III
Oral L-Arginine in Patients With Coronary Artery Disease on Medical Management
Circulation,
May 9, 2000;
101(18):
2160 - 2164.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Wallace and W. L. Tom
Interaction of L-Arginine and Phosphodiesterase Inhibitors in Vasodilation of the Porcine Internal Mammary Artery
Anesth. Analg.,
April 1, 2000;
90(4):
840 - 846.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D Tousoulis, C Tentolouris, T Crake, G Katsimaglis, C Stefanadis, P Toutouzas, and G J Davies
Effects of L- and D-arginine on the basal tone of human diseased coronary arteries and their responses to substance P
Heart,
May 1, 1999;
81(5):
505 - 511.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. Prasad, S. Husain, and A. A. Quyyumi
Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: A potential role of bradykinin
J. Am. Coll. Cardiol.,
March 1, 1999;
33(3):
796 - 804.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Quyyumi
Does acute improvement of endothelial dysfunction in coronary artery disease improve myocardial ischemia?: A double-blind comparison of parenteral D- and L-Arginine
J. Am. Coll. Cardiol.,
October 1, 1998;
32(4):
904 - 911.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. O. Cannon III
Role of nitric oxide in cardiovascular disease: focus on the endothelium
Clin. Chem.,
August 1, 1998;
44(8):
1809 - 1819.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Dakak, S. Husain, D. Mulcahy, N. P. Andrews, J. A. Panza, M. Waclawiw, W. Schenke, and A. A. Quyyumi
Contribution of Nitric Oxide to Reactive Hyperemia : Impact of Endothelial Dysfunction
Hypertension,
July 1, 1998;
32(1):
9 - 15.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|